While the PARP-1 invalidation or olaparib treatment inhibits the expression and the phosphorylation of NF-kB in small-cell lung cancer, olaparib treatment activates NF-kB in acute myeloid leukemia blasts [40,41]. The gene discussed is NFKB1; the disease is acute myeloid leukemia.